Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

Picking needles in a haystack: Exploring rare variants of a pan-cancer target in the RET landscape from 229,453 adult cancer patients.

Niamh Coleman, Vivek Subbiah Jun 01, 2025 pp. 3150-3150 10.1200/jco.2025.43.16_suppl.3150

3150 Background: Advances in precision oncology have led to the approval of tumor-agnostic therapies, and RET, due to its role as a driver of oncogenesis...

A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).

Robin Lewis Jones, Neal Shiv Chawla, Steven Attia et al. Jun 01, 2025 pp. 11506-11506 10.1200/jco.2025.43.16_suppl.11506

11506 Background: Catequentinib Hydrochloride (AL3818, Anlotinib, Catequentinib) is a novel, orally administered, small mo...

Electronic patient-reported outcome-based weight management versus usual care during induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: A phase II randomized controlled trial.

Qiu-Yan Chen, Jing Jin, Shan-Shan Guo et al. Jun 01, 2025 pp. 1503-1503 10.1200/jco.2025.43.16_suppl.1503

1503 Background: Nearly almost patients with nasopharyngeal carcinoma (NPC) experience weight loss (WL) and malnutrition during treatment. However, effect...

S1900E: A phase II study examining impact of co-mutations on sotorasib for previously treated stage IV/recurrent <i>KRAS</i> G12C mutated (MUT) non-squamous (Non-sq) non-small cell lung cancer (NSCLC) (ECOG-ACRIN led Lung-MAP Sub-study).

Sukhmani Kaur Padda, Mary Weber Redman, David E. Gerber et al. Jun 01, 2025 pp. 8518-8518 10.1200/jco.2025.43.16_suppl.8518

8518 Background: In previously treated KRAS G12C MUT NSCLC, the allosteric KRAS G12C inhibitor sotorasib had superior outcomes com...

Impact of clinical trial treatment and area deprivation index in the outcomes of adolescent and young adult patients with acute myeloid leukemia.

James Wesley Hill, Koji Sasaki, Hussein Abbas et al. Jun 01, 2025 pp. 6550-6550 10.1200/jco.2025.43.16_suppl.6550

6550 Background: Socioeconomic status (SES) is an independent prognostic factor in patients (pts) with acute myeloid leukemia (AML). Adolescent and young...

MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/iBRA-NET/AGO-B-062, NCT 05559411).

Maggie Banys-Paluchowski, Nina Ditsch, Jai Min Ryu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps627

TPS627 Background: In the last decades, the proportion of breast cancer patients receiving breast-conserving surgery has increased, reaching 70-80% in dev...

Cardiac involvement in Erdheim-Chester disease: A systematic review of presentation, management and outcome.

Ifeoma Achebe, Chukwuemeka Nzewi, Chioma Victoria Nwachukwu Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e18606

e18606 Background: Erdheim-Chester Disease (ECD) is a rare non-Langerhans cell histiocytosis characterized by multisystemic involvement, including cardiac...

Relative depth of invasion (RDI) index and clinicopathologic predictive factors for identifying high axillary nodal burden in ACOSOG Z0011–eligible breast cancer patients.

Shafeek Shamsudeen, Sajna P. V., Lista Paul et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e12585

e12585 Background: Accurate prediction of non-sentinel lymph node (nSLN) involvement remains a significant challenge in tailoring axillary management stra...

Updated efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patients with <i>PIK3CA</i> -mutant HR+HER2- advanced breast cancer: ReDiscover trial.

Sarah L. Sammons, Cristina Saura Manich, Antoine Italiano et al. Jun 01, 2025 pp. 1086-1086 10.1200/jco.2025.43.16_suppl.1086

1086 Background: Oncogenic PIK3CA mutations constitutively activate PI3Kα and drive approximately 40% of HR+HER2- breast cancer (B...

Verification of the BREASTEST assay in an Australian population: A novel liquid biopsy assay measuring lipid biomarkers for early-stage breast cancer screening.

David Speakman, Klaus-Peter Adam, Tim Huang et al. Jun 01, 2025 pp. 613-613 10.1200/jco.2025.43.16_suppl.613

613 Background: Women with dense breasts are at higher risk of developing breast cancer however there is no agreement on how to screen these women, despit...

SHR-A1811 plus adebrelimab in unresectable or metastatic triple-negative breast cancer: Results from a phase 1b/2 expansion cohort.

Yan Liang, Qingyuan Zhang, Liqiu Liao et al. Jun 01, 2025 pp. 1103-1103 10.1200/jco.2025.43.16_suppl.1103

1103 Background: SHR-A1811 is a novel HER2-directed antibody-drug conjugate with promising antitumor activity in breast cancer (BC), yielding a confirmed...

The role of a suspicion of cancer clinic in lung cancer care.

Matthew Crimmins, Shawn Michael Seibert, Trevella Fleming Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23105

e23105 Background: In 2018, Illinois Cancer Care and UnityPoint Health (now Carle Health) in a collaborative agreement, started the Suspicion of Cancer (S...

Large-scale clinical validation of a blood-based, multi-cancer, early detection test across different sample types, platforms, and populations.

Mao Mao, Yong Shen, Yong Xia et al. Jun 01, 2025 pp. 10521-10521 10.1200/jco.2025.43.16_suppl.10521

10521 Background: Many established cancer screening or diagnostic methods often face challenges in low- and middle-income countries due to high cost, comp...

Association of the number of positive lymph nodes, lymph node ratio, and log odds of positive lymph nodes with survival prognosis in N2 stage colon cancer.

Zhiyuan Gong, Yuyan Zheng, Haochen Gu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15508

e15508 Background: Colon cancer is the third most common cancer globally and a leading cause of cancer death. Accurate prognosis prediction, crucial for r...

Evaluating the relationship between insomnia, vasomotor symptoms and nocturia in patients receiving androgen deprivation therapy for prostate cancer: Results from a single centre observational study.

Stephen Mangar, Agata Baczynska, Sara Elsharkawy et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17118

e17118 Background: Insomnia in prostate cancer patients is common especially in those receiving androgen deprivation therapy (ADT) which can impact daytim...

Trop-2 expression and its prognostic impact on endometrial cancer: A real-world data analysis.

Yi Zhang, Linda Su-Feher, Kaiwen Lin et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17624

e17624 Background: Trophoblast cell surface antigen 2 (Trop-2), encoded by the transmembrane calcium signal transducer gene, TACSTD2...

Clinical factors associated with advanced colorectal neoplasia in average risk, asymptomatic individuals.

Andrew J Piscitello, Chung-Kai Sun, Amanda Culley et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15679

e15679 Background: Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in the U.S. Advanced precancerous lesions (APL) are at...

Impact of AI medical scribes on physician productivity and satisfaction in medical oncology.

Nima Toussi, Caroline Zhang, Jocelyn Kang et al. Jun 01, 2025 pp. 11167-11167 10.1200/jco.2025.43.16_suppl.11167

11167 Background: AI Scribes are a leading example of AI implementation in clinical settings, with Oncology practices demonstrating exponential uptake sin...

Development and validation of the gastric risk immuno-progression score (GRIPS) in advanced gastric and gastroesophageal junction adenocarcinoma treated with first-line chemotherapy plus nivolumab: Results from the ORACLE study.

Dario Spanu, Pina Ziranu, Andrea Pretta et al. Jun 01, 2025 pp. 4062-4062 10.1200/jco.2025.43.16_suppl.4062

4062 Background: The addition of nivolumab to chemotherapy is approved for advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma with PD-L1...

Prospective observational study on health resource utilization and patterns of care for skeletal-related events in patients with bone metastases secondary to solid tumors.

Mahmoud Abdelsatar Elshenawy, Aisha Siddique, Faaez Uddin Syed et al. Jun 01, 2025 pp. 12052-12052 10.1200/jco.2025.43.16_suppl.12052

12052 Background: Bone metastases are a common complication of advanced solid tumors, leading to significant morbidity through skeletal-related events (SR...

Quadrant of co-occurrence of circulating tumor DNA and PD-L1 expression on circulating tumor cells in monitoring disease aggressiveness and metastasis in lung cancer.

Aravindan Vasudevan, Vijay Maruti Patil, Gourishankar Aland et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15040

e15040 Background: Liquid biopsies analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) allow minimally invasive monitoring and test...

Comparative efficacy of idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma: Real-world analysis of overall survival and time to next treatment.

Eiraj Khan, Rimal Ilyas, Max Jin et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e19532

e19532 Background: Relapsed/ refractory multiple myeloma (RRMM) is a challenging disease to manage with limited treatment options. Chimeric antigen recept...

Clinical outcomes of a prospective multicenter study evaluating a combined circulating tumor DNA (ctDNA) and RNA (ctRNA) liquid biopsy assay in metastatic non-small cell lung cancer (NSCLC).

Richa Dawar, Jennifer Fu Carney, James Michael Orsini et al. Jun 01, 2025 pp. 3062-3062 10.1200/jco.2025.43.16_suppl.3062

3062 Background: Genomic profiling of metastatic NSCLC to inform targeted therapy selection is endorsed by numerous guidelines. While tissue biopsy is the...

Correlation of genetic variants and immunotherapy-combined modality with neoadjuvant therapy outcomes in microsatellite-stable rectal cancer.

Lijie Zhang, Jingwen Wang, Yaqi Wang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15640

e15640 Background: The variability in response to neoadjuvant therapy (NAT) challenges the implementation of non-operative strategies, such as the watch-a...

Treatment trends of mucinous small bowel adenocarcinoma: An NCDB analysis.

Marlaena Nooney, Jasleen Kaur Chaddha, Peter T. Silberstein Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16478

e16478 Background: Mucinous small bowel adenocarcinoma (MSBA) is an exceedingly rare histological subtype of small bowel adenocarcinoma. With adenocarcino...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page